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Abstract
Background: Among the many challenges in cancer diagnosis is the early distinction between metastatic cancer
and a secondary tumor. This difficulty stems from the lack of markers that offer high sensitivity and specificity and
can be easily applied in routine laboratory work. An example of this challenge is distinguishing gastric metastases
originating from breast cancer from a gastric primary tumor. Hepatocyte nuclear factor 4 alpha (HNF4A) has been
suggested as a potential marker in these cases.
The aim of this study was to analyze the expression of HNF4A, estrogen receptor (ER), progesterone receptor (PR)
and gross cystic disease fluid protein 15 (GCDFP-15) in a Brazilian cohort.
Methods: We performed immunohistochemistry analysis of HNF4A, ER, PR and GCDFP-15 in 126 patients divided
into three cohorts: primary breast cancer, primary gastric cancer and both types of tumors.
Results: Our data confirmed the sensitivity and specificity of the HNF4A marker compared to other currently used
clinical markers.
Conclusion: HNF4A alone could be a gold standard marker for distinguishing primary gastric cancer from breast
metastasis, thus validating its potential clinical use, especially in populations with high genetic diversity.
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Background
Breast cancer (BC) represents the major cause of cancer-
related death among women. BC classification relies on
several aspects of tumor biology, such as origin, tumor
staging (tumor/node/metastasis (TMN) classification) and
molecular expression [1, 2]. The most frequent histo-
logical subtypes of invasive carcinomas in BC are invasive
ductal carcinoma (IDC) and invasive lobular carcinoma
(ILC) [3]. Both types can metastasize to the gastrointes-
tinal (GI) tract; however, the hematogenous dissemination
patterns may differ between IDC and ILC, leading more
commonly to GI tract metastasis from ILC tumors [4–9].
The accurate diagnosis of primary gastric cancer com-
pared to gastric metastasis from BC can be difficult.
Radiological, endoscopic and histopathological findings
may be inconclusive. The clinical presentation of
metastases to stomach resembles that of primary gastric
adenocarcinoma; however, the prognosis and treatment
substantially differ among patients who present with (1)
both primary tumors (BC and gastric) and (2) primary
BC and metastases to stomach.
Recently, two studies investigating a set of several
markers to identify potential markers for discerning
primary and metastatic gastric carcinoma [10, 11]
highlighted HNF4A expression as a possible marker, but
the analyzed test cohorts were small.
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HNF4A is a nuclear transcription factor that binds
DNA as a homodimer. The encoded protein has been
suggested as a potential therapeutic target in early-stage
gastric cancer [12]. HNF4A is correlated with inva-
sion, metastasis and epithelial-to-mesenchymal transi-
tion [12, 13]. To demonstrate that HNF4A can serve
as a biomarker, it is crucial to (1) increase the size of
patient cohorts and (2) investigate populations with
different genetic backgrounds.
Therefore, the aim of this study was to evaluate the
capacity of a concise panel of known BC markers
together with GCDFP-15 and HNF4A to accurately dis-
tinguish primary gastric adenocarcinoma from metasta-
ses to stomach in the Brazilian population. HNF4A
expression, together with ER and PR expression, exhib-
ited high sensitivity (100%) and specificity (96%) in the
126 patients analyzed in our study. Moreover, our data
confirmed HNF4A as a potential marker in primary gastric
adenocarcinoma and suggest the utility of a four-marker
immunohistochemistry panel.
Methods
Patient recruitment
This retrospective study was performed at Instituto
Nacional de Câncer (INCA) in collaboration with Escola
Paulista de Medicina at Universidade Federal de São
Paulo (UNIFESP). A total of 126 women were enrolled
in this study. Patients were diagnosed with BC at INCA
between January (1997) and March (2013), with follow-
up until July (2014). The Reporting Recommendations
for Tumor Marker Prognostic Studies (REMARK) cri-
teria were followed for patient selection, assay perform-
ance, and data analysis throughout the study. The
institutional board previously approved the procedures.
The study was designed and conducted in accordance
with ethical principles for medical research involving
human subjects based on the Declaration of Helsinki.
Approval was obtained from the Ethics Committee from
INCA and UNIFESP institutes, with the following refer-
ence number: 12390213.3.00005274.
All diagnoses were made based on clinical, endoscopic
(for gastric cancer) and histopathological data.
Immunohistochemical experiments using tumor samples
Hematoxylin-eosin (HE) slides of each paraffin-embedded
block of surgical specimens and biopsy samples were
separated and analyzed by the pathologist to select slides
with a higher content of tumor tissue and slides with nor-
mal tissue present as an internal control. Siliconized slides
for immunohistochemical (IHC) analysis were produced
by cutting ten histological sections to 3-μm thickness from
each paraffin-embedded block. The following markers
were used for IHC experiments in all patients: estrogen
receptor (ER), progesterone receptor (PR), gross cystic
disease fluid protein (GCDFP-15) and hepatocyte
nuclear factor 4 alpha (HNF4A). As external positive
controls, healthy breast tissue (for ER and PR), lymph
nodal tissue (for GCDFP-15) and hepatic tissue (for
HNF4A) were used.
Immunostaining with primary antibodies against ER
(anti-human estrogen receptor α, clone 1D51 EgR at
1:1600; Dako), PR (anti-human progesterone, clone PgR
636 at 1:500; Dako), GCDFP-15 (clone 23A3 at 1:1000;
Santa Cruz Biotechnology) and HNF4A (clone H1:
sc-374229 at 1:100; Santa Cruz Biotechnology) was
performed on all samples from patients with BC and/or
gastric cancer.
The paraffin-embedded sections were heated for 30
min at 65°C, deparaffinized in xylene, and rehydrated
using an ethanol gradient at room temperature. Incuba-
tions were performed in a humidified chamber. Sections
were treated for 40 min at room temperature with 2%
bovine serum albumin and were incubated overnight at
4°C with primary anti-human antibodies against ER, PR,
Table 1 Patient clinicopathological data
Clinical data Patients number (%)
Women 126
Age at diagnosis (range, years) 60.5 (27–93)
< 60 years 66 (52.4)
> 60 years 60 (47.6)
Primary Localization
Breast 67 (53.2)
Stomach 59 (46.8)
Histological Type
Primary gastric adenocarcinoma 42 (33.3)
Primary Breast Carcinoma 42 (33.3)
Gastric metastasis from Breast carcinoma 25 (19.9)
Primary gastric adenocarcinoma and
primary breast carcinoma
17 (13.5)
Histological Grade
I-II 50 (39.7)
III 76 (60.3)
Stage
I 19 (15)
II 23 (18.3)
III 40 (31.8)
IV 43 (34.1)
Unkown 1 (0.8)
Mortality
Alive 33 (26.2)
Dead 93 (73.8)
Follow up (range, months) 56.4 (1─186.4)
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GCDFP-15 and HNF4A. The secondary antibody pro-
vided in the commercial kit was added and incubated
with the samples for 2 h. Horseradish peroxidase activity
was visualized after treatment with H2O2 and 3,3′-di-
aminobenzidine (DAB) for 5 min (Novolink Polymer
Detection Systems). In the last step, sections were
weakly counterstained with Harry’s hematoxylin (Merck).
The intensity and localization of the immunoreactivity
were examined using a photomicroscope.
Assessment of staining
Staining was interpreted by an expert pathologist
(GMV) and the investigator (PJ) at the Pathology
Division of the Instituto Nacional de Câncer (INCA).
Samples with nuclear staining were considered positive
for ER, PR and HNF4A, and samples with cytoplasmic
staining were considered positive for GCDFP-15. Immu-
nohistochemical expression was quantified according to
the following criteria: negative expression, no staining
signal; focal expression, positive staining of up to 1% of
tumor cells; limited expression, positive staining of
10-50% of the cells; and diffuse expression, positive
staining of more than 50% of the cells. To calculate the
percentages for sensitivity and specificity, values were con-
sidered negative for cases with less than 1% expression and
positive for cases with more than 1% expression.
Patient cohorts
Patients were divided into three cohort groups (n=42
each) as follows: control cohort I comprised primary breast
carcinoma patients with IDC or ILC and no other associ-
ated tumor; control cohort II included patients with pri-
mary gastric adenocarcinoma and no other associated
tumor; and test cohort III included patients present with
tumors in both breast and stomach. The test cohort III
was subdivided into two subgroups (A) metastases to
stomach derived from BC (n=25) and (B) primary breast
carcinoma patients with IDC or ILC with primary gastric
adenocarcinoma (n=17). This subdivision was based on
positive results for the HR, GCDFP-15, CK 7 and CK 20
markers (found in 55% of the patients). The control
cohorts were analyzed separately, but in the test cohort,
only the stomach tissue was evaluated for diagnosis.
Fig. 1 Representative immunohistochemistry results from the patient cohorts. a Invasive ductal carcinoma (IDC) (left) with mucin differentiation
area (right). b Invasive lobular carcinoma (ILC) (left) associated with “in situ” lobular carcinoma (right). c Poorly differentiated primary gastric
adenocarcinoma with signet ring cells (stomach). d Details at 20X magnification. e HNF4A staining in primary gastric adenocarcinoma. Nuclear
staining in a non-neoplastic gland (left): internal control and nuclear staining in poorly differentiated gastric carcinoma cells with signet ring cells.
f Metastasis from ILC to gastric mucosa. HNF4A nuclear staining in gastric cells from mucosa and non-staining from ILC cells
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Statistical analyses
For the statistical data analyses, SPSS, Excel and Project
R software were used to calculate descriptive statistics of
the variables and construct tables with diagnostic fea-
tures of HNF4A, ER, PR and GCDFP-15 tests. Sensitivity
refers to the ability of the test to classify an individual
with the event. Specificity refers to the ability of the test
to predict an individual with a non-event. Accuracy was
calculated as the proportion of correct predictions made
by using the markers [14]. Moreover, prevalence and
predictive values and Fisher’s exact test were calculated
to verify the association between the test results and the
type of marker (used for each cohort) and the associ-
ation between the test and the control cohort results
(for each marker). Fisher’s exact test evaluates the null
hypothesis of no association.
Results
Clinicopathological data
The clinicopathological data from patients showed that
the mean age upon diagnosis was 54.2 years (range 38–87)
for patients with primary breast carcinoma (cohort III-A)
and 59.3 years (range 41–93) for patients with breast
metastasis in the stomach. The mean interval between the
diagnosis of primary breast carcinoma and the detection
of gastric metastasis was 62 months (range 0–192
months). In four cases, gastric metastasis and primary
breast carcinoma were diagnosed simultaneously. Interest-
ingly, although ILC corresponds to a minor subset of BC
cases, 13 of the patients (52%) in our study had ILC. The
mean age at BC diagnosis was 57.3 years (range 34–73),
and the mean age at primary gastric carcinoma diagnosis
(cohort III-B) was 61.6 years (range 44–74). The disease-
free interval between the diagnoses in the patients with
two primary carcinomas was approximately 5 years. Three
patients had gastric carcinoma as the primary tumor, and
two patients had a concurrent diagnosis of breast and gas-
tric cancers. In cohort III-B, of the 17 patients presenting
with two primary carcinomas (both breast and gastric), 15
patients (88.2%) were diagnosed with IDC, and two were
diagnosed with ILC. Patients in cohorts I and II had a
mean age of 57.6 years (range 27–87) and 60.5 years
(range 31–78), respectively, suggesting that there was no
significant difference in age at diagnosis for the patients
with primary tumors and those with cancer metastasis.
The clinicopathological data for the patients were
obtained from their medical records and are shown in
Table 1. Representative pathology results for cohorts I,
II and III are shown in Fig. 1.
ER, PR and GCDFP-15 immunohistochemical staining
To confirm the results obtained by pathological analysis,
immunohistochemistry assays were conducted using
known clinical markers: ER, PR and GCDFP-15. First,
the three cohort groups were analyzed separately for
each marker.
Regarding ER expression, of the 25 patients in cohort
III-A, 12 patients (48%) were positive for gastric tumors.
Additionally, of the 42 patients in cohort I, 35 (83%)
were positive for ER. No staining was observed in cohort
II or cohort III-B. These results are shown in Table 2.
For the expression of PR, 6 (24%) and 31 (73.8%)
patients were positive in cohorts III-A and I, respect-
ively. Similar to ER expression, no staining was observed
Table 3 Distribution of PR expression by number and percentage in cohorts I, II and III
Histological type of cancer
Test Control Total P
Cohort III-A Cohort III-B Cohort I Cohort II n (%)
n (%) n (%) n (%) n (%)
Negative 19 (76.0) 17 (100.0) 11 (26.2) 42 (100.0) 89 (70.6) <0.0001
Positive 6 (24.0) 0 (0) 31 (73.8) 0 (0) 37 (29.4)
Total 25 (19.8) 17 (13.5) 42 (33.33) 42 (33.33) 126 (100.0)
Table 2 Distribution of ER expression by number and percentage in cohorts I, II and III
Histological type of cancer
Test Control Total P
Cohort III-A Cohort III-B Cohort I Cohort II n (%)
n (%) n (%) n (%) n (%)
Negative 13 (52.0) 17 (100.0) 7 (16.4) 42 (100.0) 79 (62.7) <0.0001
Positive 12 (48.0) 0 (0) 35 (83.3) 0 (0) 47 (37.3)
Total 25 (100.0) 17 (100.0) 42 (100.0) 42 (100.0) 126 (100.0)
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in either cohort II or III-B. These results are shown
in Table 3. GCDFP-15 immunostaining was positive
in 9 (36%) patients from cohort III-A and 15 (35.7%)
patients from cohort I. Again, no staining was observed in
either cohort II or cohort III-B. These results are
shown in Table 4.
HNF4A staining and marker-panel construction
Because HNF4A has been reported as a relevant marker
for discriminating primary and metastatic gastric carcin-
oma, we evaluated its expression alone and within two
panels (with or without HNF4A expression analysis). In
all positive cases, the expression of HNF4A was greater
than 40%. For HNF4A expression alone, the 17 patients
previously diagnosed with primary adenocarcinoma
(cohort III-B) exhibited positive immunohistochemical
staining, thus confirming their primary status. Positive
immunostaining for this marker was also observed in
one patient from cohort III-A who had been previously
diagnosed with metastatic cancer. HNF4A showed posi-
tive expression in all patients diagnosed with primary
adenocarcinoma (cohort II) and was negative in all cases
of primary breast carcinoma (cohort I). These results are
shown in Table 5.
To evaluate the diagnostic value (test) of each marker in
cohort III, the sensitivity, specificity, positive predictive
value, and negative predictive value (NPV) for breast
and gastric cancer were considered, as was the total
accuracy of each marker. As shown in Additional file 1,
the sensitivity for the ER-PR-GCDFP-15 panel was 52%;
however, when combined with the HNF4A marker, the
sensitivity reached 100.0%. Specificity was slightly
higher for the ER-PR-GCDFP-15 panel (100.0%) than
for the HNF4A marker alone (96.0%). Specificity and
NPV could not be evaluated for all four markers
because there was no HNF4A staining in BC (cohort I).
In general, including the HNF4A marker positively
increased the evaluated indicators and enhanced the dis-
crimination of primary gastric cancer and metastatic
gastric cancer.
Discussion
One important area in the study of cancer is the origin
of the tumor. There are important differences in tumor
biology between a primary tumor and a metastatic
tumor at the same site, and those peculiarities define the
prognosis and therapeutic approach.
An association has been reported to exist between BC
and gastric cancer, with the latter as a possible second
primary tumor or a metastasis site. For GIT metastasis
originating from primary BC, the stomach is one of the
most frequently affected organs [15]. Therefore, the dis-
crimination of both tumors is essential to determining a
patient’s clinical course and treatment outcome.
For this purpose, the expression of markers such as
ER, PR, and GCDFP-15 is evaluated in conjunction with
pathology analyses. However, these markers may lack
sensitivity and/or specificity. Recent studies have indi-
cated that HNF4A expression is a powerful marker for
distinguishing a gastric primary tumor from BC metasta-
sis. Koyama and colleagues demonstrated that HNF4A
could distinguish all primary gastric carcinomas from
metastatic breast carcinomas, suggesting that HNF4A
may be a highly useful marker for excluding metastatic
breast carcinoma in the diagnosis of gastric specimens
[10]. Post and colleagues showed that HNF4A is a highly
useful marker for discriminating primary and metastatic
breast carcinomas from gastric carcinomas, with a
Table 5 Distribution of HNF4A expression by number and percentage in cohorts I, II and III
Histological type of cancer
Test Control Total p
Cohort III-A Cohort III-B Cohort I Cohort II n (%)
n (%) n (%) n (%) n (%)
Negative 24 (96.0) 0 (0) 42 (100.0) 0 (0) 66 (52.4) <0.001
Positive 1 (4.0) 17 (100.0) 0 (0) 42 (100.0) 60 (47.6)
Total 25 (100.0) 17 (100.0) 42 (100.0) 42 (100.0) 126 (100.0)
Table 4 Distribution of GCDFP-15 expression by number and percentage in cohorts I, II and III
Histological type of cancer
Test Control Total p
Cohort III-A Cohort III-B Cohort I Cohort II n (%)
n (%) n (%) n (%) n (%)
Negative 16 (64.0) 17 (100.0) 27 (64.3) 42 (100.0) 102 (81.0) <0.0001
Positive 9 (36.0) 0 (0) 15 (35.7) 0 (0) 24 (19.0)
Total 25 (19.8) 17 (13.5) 42 (33.33) 42 (33.33) 126 (100.0)
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sensitivity of 99% and specificity of 100% [11], thus sup-
porting the data of Koyama and colleagues; however, both
studies examined only a few patients.
In the present work, we aimed to evaluate HNF4A
together with the expression of ER, PR, and GCDFP-15
to investigate the discrimination of cancers in 126
Brazilian patients.
Our results for the ER, PR and GCDFP-15 expression
panel are consistent with literature data, showing that
the evaluation of these proteins is specific but not suffi-
ciently sensitive to discriminate BC metastasis in the
stomach from primary gastric cancer. The analysis of
HNF4A in conjunction with the previous panel clearly
increased the diagnostic value and supported the litera-
ture data. HNF4A showed no expression in the stomach
tissue in 24 patients in cohort III-A, thus confirming the
mammary origin of the disease. One case presented
expression of HNF4A, together with negative expression
for ER, PR and GCDFP-15. This observation raised the
hypothesis that this patient could have been misdiag-
nosed, based on pathology analysis alone.
It has been discussed, in literature, that GI metastasis
from the breast vary from 0.1 to 0.3% in retrospective
series and up to 10% from autopsia series, given the diffi-
culty in diagnose [10]. Although ILC accounts for only 5%
to 10% of invasive breast lesions, most GI metastasis from
the breast originates from ILC [16]. In this study, 40% of
gastric metastasis was of ILC origin, a high percentage
compared to previous studies but still in agreement with
the data reported more recently in the literature [17].
However, 60% of gastric metastasis was of IDC origin. In
addition to sharing many clinical, radiological and endo-
scopic features with primary gastric carcinoma, metastasis
may present with signet ring cells, increasing the difficulty
of differentiation. Signet cells were observed in several of
our patients, all of whom had gastric metastasis originat-
ing from IDC (10 of 15), ratifying that such feature is not
exclusive from ILC tumors.
Conclusion
Although large prospective studies are needed to
determine whether HNF4A alone represents a gold
standard marker for distinguishing primary gastric
cancer from breast metastasis, our data from a Brazilian
cohort provide substantial insight into the use of this
marker, consistent with the existing literature data,
and evidence regarding the genetic diversity of the
Brazilian population.
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Additional file 1: Distribution of the sensitivity, specificity, positive
predictive value, negative predictive value and accuracy percentage
values for the ER, PR, GCDFP-15 and HNF4A markers. (XLS 36 kb)
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